Lorcainide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lorcainide
Accession Number
DB13653
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
RO 13-1042 / RO-13-1042
Categories
UNII
KGJ2T0N7IQ
CAS number
59729-31-6
Weight
Average: 370.916
Monoisotopic: 370.181191203
Chemical Formula
C22H27ClN2O
InChI Key
XHOJAWVAWFHGHL-UHFFFAOYSA-N
InChI
InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3
IUPAC Name
N-(4-chlorophenyl)-2-phenyl-N-[1-(propan-2-yl)piperidin-4-yl]acetamide
SMILES
CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Lorcainide.
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Lorcainide.
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Lorcainide.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Lorcainide.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Lorcainide.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Lorcainide.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Lorcainide.
AgmatineAgmatine may increase the arrhythmogenic activities of Lorcainide.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Lorcainide.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lorcainide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041918
ChemSpider
39116
ChEBI
135568
ChEMBL
CHEMBL87543
Wikipedia
Lorcainide
ATC Codes
C01BC07 — Lorcainide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00749 mg/mLALOGPS
logP4.59ALOGPS
logP4.31ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity108.18 m3·mol-1ChemAxon
Polarizability40.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Anilides / Chlorobenzenes / Piperidines / Aryl chlorides / Tertiary carboxylic acid amides / Trialkylamines / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organochlorides
show 3 more
Substituents
Phenylacetamide / Anilide / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Piperidine / Tertiary carboxylic acid amide / Amino acid or derivatives / Carboxamide group
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:46 / Updated on May 01, 2019 13:13